CELC FDA: approves gedatolisib with fulvestrant, with or without palbociclib, for hr-positive, her2-negative locally advanced or metastatic

CELC FDA: approves gedatolisib with fulvestrant, with or without palbociclib, for hr-positive, her2-negative locally advanced or metastatic breast cancer